Join the Ozempic group to help and get support from people like you.
Ozempic News (Page 3)
GLP-1 Meds Can Work Wonders for Kidney Health
TUESDAY, Feb. 11, 2025 – Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new research shows....
Can GLP-1 Meds Harm Your Eyes?
MONDAY, Feb. 10, 2025 – Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether the medications caused the eye trouble, according...
New Facial Plastic Surgery Survey Illustrates Impact of GLP-1 Receptor Agonists
FRIDAY, Feb. 7, 2025 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the field of facial plastic surgery, according to the results of...
'Ozempic Face' and Other Top Trends in Plastic Surgery
FRIDAY, Feb. 7, 2025 – Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the American Academy of Facial Plastic and Reconstructive...
Prescriptions for Obesity Management Drugs Increasing
THURSDAY, Feb. 6, 2025 – Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online search trends, according to a study published online...
Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
WEDNESDAY, Feb. 5, 2025 – Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit. A new study found that a drug in the same class called exenatide,...
FDA OK's Ozempic To Protect Kidneys in Type 2 Diabetes Patients
WEDNESDAY, Jan. 29, 2025 – A popular diabetes drug just got a major new approval – and it could be a game-changer for millions of Americans at risk for kidney failure. The U.S. Food and Drug...
FDA Approves Ozempic (semaglutide) as the Only GLP-1 RA to Reduce the Risk of Worsening Kidney Disease and Cardiovascular Death in Adults with Type 2 Diabetes and Chronic Kidney Disease
PLAINSBORO, N.J., Jan. 28, 2025 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic to reduce the risk of kidney disease worsening,...
Several Factors Play Role in Semaglutide Initiation for Obesity Without Diabetes
THURSDAY, Jan. 23, 2025 – Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes, according to a study published...
Websites Selling Compounded GLP-1 RAs Often Misinform Consumers
TUESDAY, Jan. 21, 2025 – Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers, including with respect to U.S. Food and...
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
WEDNESDAY, Jan. 22, 2025 – Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published ...
Medicare to Negotiate Prices for 15 More Drugs, Including Ozempic
WEDNESDAY, Jan. 22, 2025 – Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with disabilities, federal health officials announced in...
Popular GLP-1 Drugs Are Shaping Health Beyond Weight Loss & Diabetes
TUESDAY, Jan. 21, 2025 – Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as substance abuse, psychosis, infections and even...
Popular GLP-1 Drugs Are Shaping Health Beyond Weight Loss & Diabetes
TUESDAY, Jan. 21, 2025 – Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as substance abuse, psychosis, infections and even...
The New Definition of Obesity
The way obesity is diagnosed needs to become more sophisticated, an international commission has concluded. Using body-mass index (BMI) to tell who is overweight or obese is not reliable, and can...
Further information
Related condition support groups
Cardiovascular Risk Reduction, Chronic Kidney Disease, Diabetes, Type 2